Back Refine search Reset
Please choose a search criteria from below
Filters Clear all
Specialties
Treatments

100+ results found in London, UK

Sort by:
Showing 11 - 20 of 100+ results
Expert in: Oncology
17 years of experience
Medical Oncology

Dr Tobias Arkenau is a renowned Consultant Medical Oncologist with HCA Healthcare at numerous locations including Sarah Cannon Research Institute, The Harley Street Clinic, The Princess Grace and The Wellington Hospital. Additionally, he holds an NHS post at University College London Hospital where he is a Professorial Research Associate. 

He is a founding Medical Director of the Sarah Cannon Research Institute UK and is currently serving as the Executive Medical Director for SCRI UK and Clinical Lead for the HCA Healthcare UK Cancer Service Line. The talented physician has a wide range of experience in a variety of cancers, particularly gastrointestinal and skin cancers. 

He was awarded his medical degree from Hanover Medical School in Germany in 2000. Following this, he completed his specialist training in oncology across numerous centres of excellence including the Royal Marsden Hospital. He was awarded a Fellowship by the Royal College of Physicians, and he is a key opinion leader in his field of Gastrointestinal Cancers, Drug Development and Immunotherapy for his reserach contributions to his field. During his career, he has published numerous peer reviewed articals and book chapters and contributes regulalry at international meetings such as ASCO, ESMO and AACR. He is leading the Sarah Cannon Institute UK as a Chief and Principal Investigator of numerous clinical trials of new anti-cancer drugs including immunotherapies and cellular therapies.


Diseases, Medical Tests and Treatments
  • Immunotherapy
  • Chemotherapy
  • Clinical Trials, Phase-1 studies
  • Drug Development, Experimental Therapies
  • TIL-Therapy
  • Biological Therapy
  • Video Consultation
  • Genetic Testing (Genomics Review Board)


  • Gastrointestinal Cancer
  • Skin Cancer
  • Upper Gastrointestinal Cancer
  • Lower Gastrointestinal Cancer
  • Melanoma
  • Bile Duct Cancer
  • Bowel Cancer
  • Colon Cancer
  • Gallbladder Cancer
  • Liver Cancer
  • Oesophagus Cancer
  • Pancreatic Cancer
  • Stomach Cancer
  • Small Bowel Cancer
Read more
Expert in: Oncology
34 years of experience

Dr Katharine Pigott graduated from the University of London in 1995 having trained at The Middlesex Hospital. She specialised in Clinical Oncology training at The Westminster Hospital and Charing Cross Hospital. She also spent two years working as a research fellow at Mount Vernon Hospital and the Gray Laboratory running clinical trials in hyper fractionation and undertaking an MD in measuring late radiation damage. She took up a consultant post at The Royal Free in 1996 and worked there for twenty years specialising in the management and treatment of urological cancers and breast cancer.

During her time at The Royal Free, she was head of the Radiotherapy Department and Chair of The London Cancer Radiotherapy Expert Reference Group. Her clinical interests are research in breast and prostate cancer particularly in new radiotherapy technique and clinical trials. She was the radiotherapy lead for the TARGIT Academy at The Royal Free which taught intraoperative radiotherapy (IORT) to centres throughout the world and participated in the TARGIT trials.

She has published peer-review papers and co-edited books on the urological condition and intraoperative radiotherapy.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.


Diseases, Medical Tests and Treatments
  • Decision making for localised prostate cancer
  • Management of localised and metastatic prostate cancer
  • Management of breast cancer
  • External beam radiotherapy
  • Cyberknife
  • Rapid Arc/ Intensity-modulated radiotherapy
  • IORT intra-operative radiotherapy
  • Hormone treatment
  • Chemotherapy Radioisotope treatment
  • Decision making for localised prostate cancer
  • Management of localised and metastatic prostate cancer
  • Management of breast cancer
  • External beam radiotherapy
  • Cyberknife
  • Rapid Arc/ Intensity-modulated radiotherapy
  • IORT intra-operative radiotherapy
  • Hormone treatment
  • Chemotherapy Radioisotope treatment
Read more
Expert in: General Medicine
16 years of experience

Professor Peter Schmid is the Clinical Director of the St. Bartholomew Breast Cancer Centre, and Honorary Consultant Medical Oncologist and lead of the Cancer Immune Therapy group at Barts Hospital. He is also Professor of Cancer Medicine and Lead of the Centre of Experimental Cancer Medicine at Barts Cancer Institute.

Professor Schmid studied medicine in Munich and Aberdeen. He was awarded scholarships by the German National Academic Foundation, the German Academic Exchange Service and the Hanns-Seidel-Foundation. Following this he completed specialist training in internal medicine, medical oncology and haematology in Berlin. Subsequently he undertook an MD in Clinical Chemistry at the Technical University Munich and a PhD in Medical Oncology at the Charité University in Berlin. In 2005, Professor Schmid moved to the UK and was appointed as Senior Clinical Lecturer and Director of the Hammersmith Early Clinical Trials Unit at Imperial College London. He was subsequently made Foundation Chair in Cancer Medicine at the University of Sussex.

He specialises in breast cancer, lung cancer and cancer immune therapy and is renowned internationally for this work in cancer immunotherapy. He was instrumental in the formation of the Cancer Immune Therapy group at Barts Hospital, which has become recognised globally as a leader in this field.

Professor Schmid has a particular research interest in triple negative breast cancer and endocrine resistance and has led more than 20 clinical studies and several translational research programmes in these areas. He also has an interest in personalised cancer medicine using novel biomarkers and innovative, biomarker-driven clinical trial strategies to develop new treatment strategies. He currently leads an international group to establish blood-based circulating biomarkers.

He has authored or co-authored more than 150 publications and has published a book on the management of bone metastases. He is also regularly invited to speak at major international cancer conferences. Professor Schmid is a member of the breast cancer faculty of the European Society of Medical Oncology and has chaired several medical research committees. He was awarded the Breast Cancer Research Award 2012 by German Patient group Mammazone.

Professor Schmid has a strong interest in patient-doctor communication, for a number of years, he ran a programme training oncologists and oncology nurses in communication.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.


Diseases, Medical Tests and Treatments
  • Chemotherapy 
  • Immunotherapy 
  • Breast Cancer
  • Lung Cancer 
Read more
Expert in: Oncology
24 years of experience
Clinical Oncology

Dr Stephen Morris is a consultant in Clinical Oncology at Guy's and St Thomas' Hospitals, specialising in the management of skin and urological cancers. He specialises in brachytherapy, external beam radiotherapy and chemotherapy for prostate cancer at Guys Hospital. He also leads the chemotherapy and radiotherapy service for cutaneous lymphoma at the St Johns Institute of dermatology at Guys.

Dr Morris completed his initial medical training at Guy's and St Thomas' medical school. Following this, he trained in clinical oncology at the Royal Marsden Hospital and the Guy's and St Thomas' Cancer Centre. At Guys he was involved in setting up the dynamic prostate brachytherapy service and since his appointment as a consultant, has continued to innovate in the field, working for ever-improving outcomes for patients.

In addition to his work in research and clinical trials, he has led the design and implementation of a new modern Total Skin Electron Beam technique for cutaneous lymphoma, IMRT and IGRT for prostate cancer and more recently has developed and implemented the use of the SpaceOAR and Auto Beam Hold intra fraction IGRT technique for prostate cancer. Dr Morris is also a keen teacher and involved in education as a tutor for clinical oncology.


Diseases, Medical Tests and Treatments
  • Prostate brachytherapy
  • Radiotherapy
  • Chemotherapy
  • Clinical Trials
  • Urological oncology 
  • Dermatological oncology
  • Cutaneous lymphoma and melanoma
  • Prostate cancer

 

Read more
Expert in: Oncology
25 years of experience

Martin graduated from the University of Newcastle upon Tyne and gained general medical experience in New Zealand, Australia and the United Kingdom, becoming a member of the Royal College of Physicians (UK) in 2000. Since then he has been working in cancer care, training in Medical Oncology at the Oxford Radcliffe and Royal Marsden NHS Trusts. During this time, he achieved a PhD at the Institute for Cancer Research, London, and was awarded the EORTC-PAMM Young Investigator Award in 2004. He completed his specialist training in Medical Oncology in 2008 and was appointed as a UCL Clinical Senior Lecturer and UCH Consultant in Medical Oncology in 2009. Since then he has been running a research-based practice and has been principal/chief investigator for more than 20 early and late phase clinical trials.

Martin is involved in the management of patients with both lung and head and neck cancers. He is interested in drug development and in using the increasing understanding of cancer biology to design studies that distinguish patient populations most likely to gain benefit from new drugs and new drug combinations. He has a particular interest in cancer biology that leads to the development of both lung and head and neck cancers.


Diseases, Medical Tests and Treatments
  • Chemotherapy
  • Lung and head and neck cancers
  • Drug development 
  • Cancer biology
Read more
Expert in: Oncology
18 years of experience

Dr Timothy Robert Crook is a Consultant in Medical Oncology who works at The Princess Grace Hospital, The Harley Street Clinic, The Wellington Hospital and LOC.

He specialises in Bladder cancer, breast disease, chemotherapy, kidney cancer, oncology and skin cancer.


Diseases, Medical Tests and Treatments
  • Bladder cancer
  • Breast disease
  • Chemotherapy
  • Kidney cancer
  • Oncology
  • Skin cancer
  • Bladder cancer
  • Breast disease
  • Chemotherapy
  • Kidney cancer
  • Oncology
  • Skin cancer
Read more
Expert in: Oncology
21 years of experience
Medical Oncology

Dr Thomas Newsom-Davis a Consultant Medical Oncologist at Chelsea and Westminster Hospital. He specialises in thoracic malignancies, especially lung cancer and mesothelioma. In 2015, he was awarded the Macmillan Innovation Excellence Award.

Training

Dr Newsom-Davis completed his training at University College and Middlesex School of Medicine, London, in 1998, including First Class honours for his BSc. He went on specialise in medical oncology at Charing Cross and Hammersmith Hospitals and completed a PhD in tumour immunology. He was appointed to Chelsea & Westminster Hospital in 2010.

Current Roles

Dr Newsom-Davis leads the lung cancer service for Chelsea & Westminster Hospital, and is Vice Chair of the British Thoracic Oncology Group (BTOG) Steering Committee, an organistion which supports and educates thoracic oncology profressionals across the United Kingdom. Dr Newsom-Davis is Chair of the Harley Street Clinic lung cancer multidisciplinary team (MDT), and Chair of the HCA Healthcare UK Thoracic Oncology Board.

Research

Dr Newsom-Davis has an active clinical trial portfolio, and has presented his work at National and International meetings. He has been an invited lecturer for organisations including the Royal College of Physicians, European Society of Medical Oncology, International Association for the Study of Lung Cancer, British Medical Association and the Association of Cancer Physicians.

It is important that HCA is transparent about our relationship with those doctors who provide us with clinical guidance on delivering the best possible care to patients and operating our hospitals safely and efficiently. We set out here some of the ways in which we work together and the amount we pay this doctor for such services.

Diseases, Medical Tests and Treatments

  • Immunotherapy, Targeted Therapy, Chemotherapy
  • Lung Cancer
  • Mesothelioma
Read more
Expert in: Oncology
16 years of experience

Dr Jonathan Krell is a Consultant Oncologist specialising in breast and gynaecological cancers, with particular interest in cancer genetics and hereditary malignancies, especially with respect of BRCA and other gene mutations. His clinical focus is on the systemic management of patients with gynaecological and breast cancers. 

Dr Krell qualified in medicine at Leeds University Medical School, where he also gained a first class honours degree in Pharmacology. He completed junior doctor positions at St James’ Hospital, Leeds and St Thomas’ Hospitals in London. He then undertook oncology training at Charing Cross and Hammersmith Hospitals.

His PhD work was funded by the Medical Research Council and this investigated the interplay between genetic mutations, DNA damage and the response to cancer therapeutics. Dr Krell is a leading member of the translational research team within the Cancer Research UK and Ovarian Cancer Action centres at Imperial College that aim to overcome resistance to current anti-cancer agents in ovarian and breast cancer.

Dr Krell has published more than 100 peer-reviewed papers in academic journals and he regularly presents on his research at national and international conferences.

 


Diseases, Medical Tests and Treatments
  • Chemotherapy
  • Radiotherapy
  • Genetic Testing
  • Breast Cancer
  • Ovarian Cancer
  • Gynaecological Cancers

 

Read more
Expert in: Oncology
33 years of experience

Professor John Bridgewater is a Consultant Medical Oncologist and Clinical Researcher at the UCL Cancer Institute. He specialises in gastrointestinal oncology, with a particular interest in biliary tract cancers and carcinomas of unknown primary origin.

After studying medicine at Oxford and University College London, he went on to specialise in Medical Oncology at the Middlesex, Mount Vernon and Royal Marsden Hospital. He was awarded a PhD by the Institute of Cancer Research for research into gene therapy. In 1999 he was appointed as a Senior Lecturer in Medical Oncology at UCL.

Professor Bridgewater leads the National Cancer Research Institute subgroup in hepatobiliary malignancy and also has a laboratory programme at the UCL Cancer Institute investigating carcinoma of unknown primary origin. He is also active in trials across the gastrointestinal portfolio and has been the chief investigator on a number of landmark studies into gastrointestinal and biliary tract cancers. As well as his clinical and research work, he also serves on a number of committees including The National Institute for Health and Care Excellence (NICE) and National Cancer Research Institute (NCRI). 


Diseases, Medical Tests and Treatments
  • Chemotherapy 
  • Bilary Cancer 
  • Bowel Cancer 
  • Cancer Unknown Primary
  • Gastro-intestinal Cancers
  • Liver Cancer 

 

Read more
Expert in: Oncology
27 years of experience

Dr Susan Cleator is a Consultant Clinical Oncologist with extensive experience in breast, colorectal and lymphomatous cancers. She has a specialist interest in early breast cancer and treatment of breast cancer in young women.

After studying medicine at Oxford University and Hospitals, she completed her specialist oncology training at the Charing Cross, Hammersmith, Mount Vernon and The Royal Marsden Hospitals. During this time she spent three years working on her PhD project at the Institute of Cancer Research and Royal Marsden Hospital. Her research focused on identifying a molecular assay for predicting the response of breast cancers to chemotherapy.

Dr Cleator works closely with a multi-disciplinary team at St Mary’s hospital where she is responsible for the chemotherapy and radiotherapy aspect of the patient’s treatment. She is actively involved in research into both breast and colorectal cancers, and has been published in a number of peer-reviewed journals. She is also a member of a number of research groups including the National Cancer Research Institute (NCRI) Breast Cancer Studies Group (BCSG).


Diseases, Medical Tests and Treatments
  • Chemotherapy 
  • Radiotherapy 

 

 

 

  • Breast Cancer 
  • Gastro-intestinal cancers 

 

 

 

Read more